Grantclosed🌐 United StatesRFA-HL-26-015

NHLBI SBIR Phase IIB Small Market Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional)

National Institutes of Health

Details?

Posted: Nov 18, 2024
Response deadline: Nov 17, 2025, 12:00 AM UTC
Type: Grant
Category: 93.840, 93.350, 93.839, 93.837, 93.233, 93.838
Status: closed
Buyer: National Institutes of Health
Department: HHS-NIH11
Jurisdiction: United States
Reference #: RFA-HL-26-015

Doc Type: synopsis
Opp Status: archived

Similar past solicitations

NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional)
United States · Nov 18, 2024
NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) for Clinical Trials and Clinical Research (R44 Clinical Trial Optional)
United States · Jun 20, 2024
Secondary Analysis of Existing Datasets in Heart, Lung, and Blood Diseases and Sleep Disorders (R21 Clinical Trial Not Allowed)
United States · Dec 30, 2024
NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) for Pre-Clinical Research (R44 Clinical Trial Not Allowed)
United States · Jun 21, 2024
Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (R01 Clinical Trial Optional)
United States · Dec 31, 2024
Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P50 Clinical Trial Optional)
United States · Dec 31, 2024

Finding similar opportunities…

This listing is a summary from United States's open procurement data. We ingest every field the feed publishes; the full solicitation documents are on the source portal.